Study supports 7-day protection for Vanguard B Oral in dogs
Bottom line
Version 1 — Brief
A new study in the American Journal of Veterinary Research reports that a single oral dose of Zoetis’ live-attenuated Bordetella bronchiseptica vaccine, Vanguard B Oral, provided protective immunity in dogs just 7 days after vaccination. In the randomized, blinded, controlled challenge study, 40 eight-week-old Beagle puppies received either vaccine or placebo on day 0, then were exposed to aerosolized virulent B. bronchiseptica on day 7. The paper adds peer-reviewed evidence for a product already marketed for dogs 8 weeks and older, which Zoetis says is the only oral Bordetella vaccine with a USDA-verified 1-year duration of immunity. (papers.ssrn.com)
Why it matters: For veterinary teams, rapid onset of immunity matters most when dogs are headed into higher-risk settings like boarding, daycare, shelters, grooming, shows, or clinics, where Bordetella exposure is common and canine infectious respiratory disease complex can spread quickly. Cornell notes that Bordetella is highly contagious, commonly transmitted by aerosols and close contact, and especially relevant in grouped housing or congregate environments. An oral option with evidence of protection by day 7 may help practices counsel pet parents who want mucosal protection without intranasal administration, while still setting expectations that Bordetella vaccination reduces disease risk and severity rather than eliminating all CIRDC risk. (vet.cornell.edu)
What to watch: Watch for whether this study changes clinic vaccination protocols, especially for dogs needing short-notice protection before boarding or other group exposure. (papers.ssrn.com)
Key facts
- Study
- Randomized, blinded, placebo-controlled challenge study
- Sample size
- 40 eight-week-old Beagle puppies
- Vaccine
- Zoetis Vanguard B Oral
- Agent
- Live-attenuated Bordetella bronchiseptica vaccine
- Key finding
- Protected dogs against challenge 7 days after vaccination
- Challenge
- Aerosolized virulent B. bronchiseptica on day 7
- Indication
- Healthy dogs 8 weeks of age or older
- Duration of immunity
- Zoetis says it is the only oral Bordetella vaccine with USDA-verified 1-year duration of immunity
Version 2 — Full analysis
A newly published American Journal of Veterinary Research study adds peer-reviewed support for Zoetis’ Vanguard B Oral, finding that dogs given the live-attenuated oral Bordetella bronchiseptica vaccine were protected against challenge just 7 days after vaccination. The study evaluated onset of immunity in a randomized, blinded, placebo-controlled design using 40 eight-week-old Beagle puppies, with challenge exposure delivered by aerosol on day 7. (papers.ssrn.com)
The finding lands in a familiar clinical problem: dogs are often vaccinated against Bordetella shortly before boarding, daycare, grooming, transport, shelter intake, or other group exposure. Cornell’s canine health guidance describes Bordetellosis as a highly contagious component of canine infectious respiratory disease complex, spread primarily through coughing, sneezing, direct contact, and contaminated objects, with increased prevalence wherever dogs are housed or gathered together. The incubation period is about six days, which makes time-to-protection especially relevant in real-world scheduling decisions. (vet.cornell.edu)
According to the study summary and product materials, Vanguard B Oral is indicated for healthy dogs 8 weeks of age or older. Zoetis says the product is the only oral Bordetella vaccine with USDA-verified 1-year duration of immunity. That longer-duration positioning matters commercially and clinically, because Bordetella revaccination timing can vary by risk profile, with some high-exposure dogs receiving more frequent boosters depending on practice policy or facility requirements. (zoetisus.com)
The broader vaccine landscape also gives this paper some context. Oral and intranasal Bordetella products are used because they target mucosal immunity and are often chosen for dogs that need relatively fast protection. Consumer-facing veterinary guidance cited by the AKC, including comments from shelter medicine expert Cynda Crawford, DVM, PhD, notes that these vaccines generally do not provide sterile immunity, but can reduce clinical severity, progression, and duration of shedding. That distinction is important for pet parent counseling: vaccination is a risk-reduction tool, not a guarantee against all coughing illness in CIRDC settings. (akc.org)
There’s also precedent for interest in 7-day oral Bordetella protection. Earlier published work in Veterinary Record Open found that oral and intranasal Bordetella vaccination could both prevent disease 7 days after vaccination in challenge models, though that study involved other commercial products. The new AJVR paper therefore strengthens the evidence base specifically for Vanguard B Oral, rather than introducing the concept of rapid mucosal Bordetella protection for the first time. (bvajournals.onlinelibrary.wiley.com)
Why it matters: For veterinary professionals, the practical value is less about novelty than confidence and fit. A peer-reviewed demonstration of protection by day 7 supports use of an oral Bordetella option when intranasal delivery is poorly tolerated, logistically difficult, or less appealing to pet parents. It may be especially useful in general practice, shelter medicine, and high-throughput preventive care settings where minimizing administration stress and aligning vaccination timing with imminent exposure are everyday concerns. At the same time, clinicians will still need to frame Bordetella vaccination within the broader CIRDC picture, where multiple pathogens, co-infections, and environmental pressures shape outcomes. (papers.ssrn.com)
Industry context suggests competition in this segment is active. Zoetis has continued to promote its Vanguard respiratory line, including a March 21, 2025 announcement about a reformulated Vanguard B Intranasal product, while Elanco announced USDA approval for an oral Bordetella vaccine, TruCan Ultra B (Oral), in early 2026. That means evidence around onset, duration, ease of administration, and workflow fit is likely to matter as practices compare products. (zoetisus.com)
What to watch: The next question is whether this publication drives broader uptake of oral Bordetella vaccination in dogs needing fast pre-exposure coverage, and whether competing manufacturers respond with more head-to-head or field-based data on onset, shedding, and performance in real-world CIRDC settings. (bvajournals.onlinelibrary.wiley.com)